Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/211349
Authors: 
Salerno, Mario Sergio
Matsumoto, Cristiane
Ferraz, Isabela
Year of Publication: 
2018
Series/Report no.: 
Texto para Discussão 2398
Abstract (Translated): 
The text discusses possibilities of public policies for the development of biopharmaceuticals in Brazil, with emphasis on monoclonal antibodies (mAbs). First section discusses the basic concepts about biotechnology, biopharmaceuticals and monoclonal antibodies in order to sustain the later development of the work. Next, it discusses the evolution of the global pharmaceutical industry, emphasizing biopharmaceuticals, its value chain and general industry challenges. Then, it discusses the Brazilian scenario, emphasizing industry structure, demand, mainly of SUS (Brazilian Health System), regulation and actors involved in the chain or value network. Finalizing the text, a discussion on possibilities and alternatives for the development of public policies that help to leverage the development of this relevant industry.
Subjects: 
biopharmaceuticals
drug innovation
public policy
JEL: 
O38
L65
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.